Biogen stock
BIIBNASDAQBiogen Inc., HealthcareISIN US09062X1037
60Score 60 out of 100, Neutral
Price and trend
82 / 100
Price history
+55% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 22% above it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 50).
The price is 1.7% below its 52-week high. Largest decline in 20 years: 76% (March 2015 to April 2025).
Chart figures for advanced users
- SMA 50$232.77
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$204.77
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)50
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$161.48
- The lowest closing price of the last twelve months.
- Resistance$254.87
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Biogen Inc. belongs to the Drug Manufacturers (General) industry (United States) and, with a market value of $37.03B, is number 18 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $9.81B (up 1.4% year on year) and earnings of $1.29B (down 20.8%).
- For fiscal 2026, analysts expect on average revenue of $10.58B (up 7.9%) and adjusted earnings per share of $12.49 (down 18.3%).
Show more
- MEQIRI Score 60 out of 100 (Neutral): rank 266 of 702 in Healthcare, median 53.
- The P/E is 106.4 because earnings over the last twelve months collapsed; on the expected earnings of the next twelve months it is 15.9 (Drug Manufacturers (General) median 25.7). The P/E therefore does not count in the score.
- Our model puts fair value at $357.94, with the price 30% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.Fundamentals 81
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 81
- Share buybacksShare count down 9% since 2020.Capital allocation 61
Weaknesses
- Earnings per share fallingDown 18.7% a year since 2020.Growth 6
- Revenue shrinkingRevenue down 6.1% a year since 2020.Growth 6
- Margin fallingOperating margin 19.1%, average of the prior years 25.7% (to 2024).Profitability 38
Its standout strengths are momentum and technical analysis, while profitability and growth hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- low growth grade (crashed less often in the backtest)
- solid fundamentals
- calm price action
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $275.34 and expensive above $511.35 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $294.74, at 7.8% it would be $453.05.
Possible value trap: looks cheap, but weak growth.
Valuation metrics
From the cash-flow model alone; after a one-off collapse in earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 3.1% on the twelve months before. Revenue has grown solidly since 2006, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 70%, operating 19%, net 13%. Last 12 months: net 3%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 5 Feb 2027in 84 days
- Last reported
- 28 Oct 2026EPS reported $2.62 (expected $1.99)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $12.49+0.6%
- Revenue
- $10.58B+1.2%
- Earnings per share
- $16.22−1.7%
- Revenue
- $10.78B+1.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −1.2%Biogen raised the lower end of its 2026 non-GAAP EPS guidance to $12.20 to $13.00, mainly due to faster Apellis integration and synergy capture plus lower-than-expected dilution from the acquisition.
The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $239,750 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Biogen
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 60
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- GSKGSK $101.51B69
- Chugai Pharmaceutical4519.T $73.66B78
- BayerBAYN.DE $61.57B53
- Otsuka Holdings4578.T $40.24B78
- Daiichi Sankyo4568.T $32.6B73
- Astellas Pharma4503.T $30.07B87
- OrionORNBV.HE $15.97B86
- CSPC Pharmaceutical Group1093.HK $12.16B79
ETFs that hold Biogen
Held by 137 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.86% | 0.49% | €26.29M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 2.37% | 0.35% | €1.25B |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 1.91% | 0.25% | €45.16M |
Show 5 more
| iShares Healthcare Innovation UCITS ETF2B78 | 1.44% | 0.40% | €1.5B |
| UBS Global Gender Equality UCITS ETF hEUR accGGUE | 1.12% | 0.23% | €189.75M |
| iShares Ageing Population UCITS ETF2B77 | 0.61% | 0.40% | €813.42M |
| UBS Factor MSCI USA Prime Value Screened UCITS ETF USD disUBUS | 0.55% | 0.25% | €130.8M |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.55% | 0.12% | €1.39B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Jun 2023)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.